Literature Review
of articles in

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

Article · Literature ReviewinExpert Review of Vaccines 12(7):747-58 · July 2013with32 Reads
DOI: 10.1586/14760584.2013.811188 · Source: PubMed
With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In this review, the authors introduce emulsion adjuvant composition and history before detailing the most recent findings from clinical and postmarketing data regarding the effects of emulsion adjuvants on vaccine immunogenicity and safety, with emphasis on the most widely distributed emulsion adjuvants, MF59® and AS03. The authors also present a summary of other emulsion adjuvants in clinical development and indicate promising avenues for future emulsion-based adjuvant development. Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles.

Do you want to read the rest of this article?

    New vaccine approaches based on subunit vaccines and on highly purified recombinant proteins use adjuvants to compensate for the loss of immunostimulatory components that are naturally present in whole cell vaccines. The development of adjuvanted influenza vaccines comprising squalene emulsion adjuvants effective against pandemic influenza strains highlights the contribution of novel adjuvants... [Show full abstract]
      Emulsion adjuvants for human vaccines have evolved gradually over the last century. Current formulations are the result of many refinements to their composition and manufacturing, as well as optimization for safety and efficacy. Squalene has emerged as being particularly suitable for the manufacturing of safe oil-in-water (O/W) adjuvants for parenteral applications due to its biocompatibility... [Show full abstract]
      December 2013 · Nature medicine
        Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the... [Show full abstract]
        October 2013
          Eine Metaanalyse aus den USA hat Vermutungen entkräftet, dass Impfungen, explizit gegen das Influenza-A-Virus H1N1, zu einer erhöhten Häufigkeit des Guillain-Barré-Syndroms führen können.
          Discover more